Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Oramed Pharmaceuticals Inc (ORMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10061)・商品コード:DATA904C10061
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13
Equity Offering 14
Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16
Oramed Pharma Raises USD12 Million in Private Placement of Shares 17
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 21
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 23
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 24
Oramed Pharma Completes Private Placement Of Units US$5 Million 25
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 26
Acquisition 27
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
Oramed Pharmaceuticals Inc – Key Competitors 29
Oramed Pharmaceuticals Inc – Key Employees 30
Oramed Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 31
Recent Developments 32
Corporate Communications 32
Feb 28, 2018: Oramed Appoints Robert Henry and Jane Reusch to its Scientific Advisory Board 32
Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 33
Product News 34
05/02/2017: Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13
Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16
Oramed Pharma Raises USD12 Million in Private Placement of Shares 17
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 21
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 23
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 24
Oramed Pharma Completes Private Placement Of Units US$5 Million 25
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 26
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
Oramed Pharmaceuticals Inc, Key Competitors 29
Oramed Pharmaceuticals Inc, Key Employees 30
Oramed Pharmaceuticals Inc, Subsidiaries 31
Oramed Pharmaceuticals Inc, Joint Venture 31

List of Figures
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10061)販売に関する免責事項を必ずご確認ください。
★調査レポート[Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆